MARKET

AQST

AQST

Aquestive Therapeutics
NASDAQ
3.950
-0.010
-0.25%
After Hours: 3.900 -0.05 -1.26% 19:09 02/20 EST
OPEN
3.930
PREV CLOSE
3.960
HIGH
4.060
LOW
3.905
VOLUME
1.97M
TURNOVER
--
52 WEEK HIGH
7.55
52 WEEK LOW
2.120
MARKET CAP
481.91M
P/E (TTM)
-5.6180
1D
5D
1M
3M
1Y
5Y
1D
Aquestive announces poster presentations on Anaphylm at AAAAI meeting
TipRanks · 2d ago
Aquestive Therapeutics Announced Multiple Poster Presentations Highlighting Data From Anaphylm (dibutepinephrine) Sublingual Film For Severe Allergic Reactions, Including Anaphylaxis
Benzinga · 2d ago
Aquestive Therapeutics to Present New Anaphylm Clinical Data at AAAAI Annual Meeting
Reuters · 2d ago
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
Barchart · 3d ago
Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity
TipRanks · 4d ago
Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer
TipRanks · 4d ago
Aquestive Therapeutics Names Dr. Matthew Greenhawt Chief Medical Officer
Reuters · 4d ago
AQUESTIVE THERAPEUTICS APPOINTS INTERNATIONALLY RECOGNIZED ALLERGIST DR. MATTHEW GREENHAWT AS CHIEF MEDICAL OFFICER
Reuters · 4d ago
More
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.

Webull offers Aquestive Therapeutics Inc stock information, including NASDAQ: AQST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AQST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AQST stock methods without spending real money on the virtual paper trading platform.